Document is current

Article History

Received: 1 December 2025

Revised: 9 March 2026

Accepted: 9 March 2026

First Online: 28 March 2026

Competing interests

: JAPS received research grants from Sanofi, Incyte and Amge; consulting fees from Gilead, J&J, Novartis, BMS, Sanofi, Jazz pharmaceuticals, Incyte, GSK, Amgen; honoraria or travel support from Gilead, J&J, Novartis, BMS, Sanofi, Jazz pharmaceuticals, Incyte, GSK, Amgen, MDS. CCL received honoraria or travel support from Jazz pharmaceuticals. DM received research grants from Novartis, Sanofi, CSL Behring; consulting fees from Novartis, Incyte, Sanofi, Jazz pharmaceuticals; honoraria or travel support from Sanofi, Novartis, Jazz pharmaceuticals; fees for participation in review activities such as data monitoring boards or advisory boards from Incyte, Sanofi. AS received consulting fees from Alexion, Gilead, MaaT pharma, Novartis, Basilea, Sanofi. AS received honoraria from Pfizer satellite symposia, Pierre Fabre; fees for participation in review activities such as data monitoring boards or advisory boards from Alexion, Gilead, Maat Pharma, Novartis, Basilea, Sanofi. PAC received honoraria or travel support from Kite, Amgen, Macopharma, Gilead, Therakos, Novartis. LG received travel support from Gilead. LG received research grants and consulting fees from Grifols, Abbvie. RD received consulting fees from Sanofi, Novartis. AH received travel support from Sanofi, Novartis. FM received honoraria or travel support from Gilead, Sanofi, Novartis, BMS, Astrazeneca, Therakos, Priothera, MSD, Jazz pharmaceuticals. MM received research grants from Sanofi, Novartis, Janssen, Jazz pharmaceuticals; consulting fees from Adaptive Biotechnologies, Amgen, Astellas, BMS, GSK, Janssen, Jazz Pharmaceuticals, Novartis, Pfizer, Sanofi, Stemline, Takeda; honoraria from Adaptive Biotechnologies, Amgen, Astellas, BMS, GSK, Janssen, Jazz Pharmaceuticals, Novartis, Pfizer, Sanofi, Stemline, Takeda, MaaT pharma; fees for participation in review activities such as data monitoring boards or advisory board from Jenssen; holds a role on the board, society or committee of EBMT, IACH. HJP, IF, BKM, received consulting fees from Maat Pharma. BKM received travel support from Maat Pharma. MB, EP are employees and stockholders of MaaT Pharma. HJP is stockholder of MaaT Pharma. JC, MC, SF, LLC, PT, A Bauhofer and A Benzaquen declare no competing interests.